Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases.
Ticker:
RLYB
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
RLYB212
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
